AcelRx Announces Primary Endpoint Met in Phase 3 Non-Inferiority Study of Sublingual Sufentanil NanoTab PCA System vs. IV PCA Morphine for Post-Operative Pain

AcelRx Announces Primary Endpoint Met in Phase 3 Non-Inferiority Study of Sublingual Sufentanil NanoTab PCA System vs. IV PCA Morphine for Post-Operative Pain

-In this open-label study, the Sufentanil NanoTab PCA System also demonstrated statistical superiority to IV PCA morphine for primary endpoint of Patient Global Assessment of method of pain control

document.addEventListener("googletagEvent", function() { googletag.cmd.push(function() { googletag.display('ad-slot_1__mobile'); }); }); - Nurses and patients rated Sufentanil NanoTab PCA System higher for Overall Satisfaction and Ease of Care compared to IV PCA morphine - AcelRx to conduct conference call and webcast today, November 15, at 8:00 a.m. EST (5:00 a.m. PST) to discuss top-line results in detail
Read more on